The latest price target for United Therapeutics (NASDAQ:UTHR) was reported by Goldman Sachs on November 1, 2024. The analyst firm set a price target for $302.00 expecting UTHR to fall to within 12 months (a possible -19.01% downside). 25 analyst firms have reported ratings in the last year.

The latest analyst rating for United Therapeutics (NASDAQ:UTHR) was provided by Goldman Sachs, and United Therapeutics maintained their neutral rating.

The last upgrade for United Therapeutics Corp happened on February 12, 2024 when Goldman Sachs raised their price target to $215. Goldman Sachs previously had a sell for United Therapeutics Corp.

The last downgrade for United Therapeutics Corp happened on July 11, 2024 when Morgan Stanley changed their price target from $310 to $321 for United Therapeutics Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United Therapeutics was filed on November 1, 2024 so you should expect the next rating to be made available sometime around November 1, 2025.

While ratings are subjective and will change, the latest United Therapeutics (UTHR) rating was a maintained with a price target of $243.00 to $302.00. The current price United Therapeutics (UTHR) is trading at is $372.89, which is out of the analyst’s predicted range.